Persistence and baseline determinants of seropositivity and reinfection rates in health care workers up to 12.5 months after COVID-19

We assessed the duration and baseline determinants of antibody responses to SARS-CoV-2 spike antigens and the occurrence of reinfections in a prospective cohort of 173 Spanish primary health care worker patients followed initially for 9 months and subsequently up to 12.5 months after COVID-19 sympto...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:BMC medicine 2021-06, Vol.19 (1), p.1-155, Article 155
Hauptverfasser: Dobaéo, Carlota, Ramírez-Morros, Anna, Alonso, Selena, Vidal-Alaball, Josep, Ruiz-Olalla, Gemma, Vidal, Marta, Rubio, Rocío, Cascant, Emma, Parras, Daniel, Rodrigo Melero, Natalia, Serra, Pau, Carolis, Carlo, Santamaria, Pere, Forcada, Anna, Mendioroz, Jacobo, Aguilar, Ruth, Moncunill, Gemma, Ruiz-Comellas, Anna
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:We assessed the duration and baseline determinants of antibody responses to SARS-CoV-2 spike antigens and the occurrence of reinfections in a prospective cohort of 173 Spanish primary health care worker patients followed initially for 9 months and subsequently up to 12.5 months after COVID-19 symptoms onset. Seropositivity to SARS-CoV-2 spike and receptor-binding domain antigens up to 149–270 days was 92.49% (90.17% IgG, 76.3% IgA, 60.69% IgM). In a subset of 64 health care workers who had not yet been vaccinated by April 2021, seropositivity was 96.88% (95.31% IgG, 82.81% IgA) up to 322–379 days post symptoms onset. Four suspected reinfections were detected by passive case detection, two among seronegative individuals (5 and 7 months after the first episode), and one low antibody responder. Antibody levels significantly correlated with fever, hospitalization, anosmia/hypogeusia, allergies, smoking, and occupation. Stable sustainment of IgG responses raises hope for long-lasting COVID-19 vaccine immunity.
ISSN:1741-7015
1741-7015
DOI:10.1186/s12916-021-02032-2